D013450Chemicals & DrugsD02.886.59026430.979943Sulfonesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson28427013Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQMCancer treatment reviewsThe accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.Cancer Treat Rev2017-03-30T00:00:002017The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.30333224Coffey GP, Feng J, Betz A, Pandey A, Birrell M, Leeds JM, Der K, Kadri S, Lu P, Segal J, Wang YL, Michelson G, Curnutte JT, Conley PBClinical cancer research : an official journal of the American Association for Cancer ResearchCerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. Clin Cancer Res. 2019 02 15; 25(4):1174-1184.Clin Cancer Res2018-10-17T00:00:002018Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.29969688Lederer PA, Zhou T, Chen W, Epshtein Y, Wang H, Mathew B, Jacobson JRVascular pharmacologyAttenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase. Vascul Pharmacol. 2018 11; 110:16-23.Vascul Pharmacol2018-06-30T00:00:002018Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase.1.452230.0052632926research area of0.9719350.0053710261subject area forJeremySegalJeremy Segal0.000000000000000.000000000000002880Segal, JeremyProfessorMedicine-Hematology and OncologyMedicinePathologyUniversity of ChicagoLucyGodley22VmD60QeczMknJtY0fp/Cv/+94=Lucy Godley41.78927490000000-87.601250000000001017Godley, LucyProfessorBijiMathewBiji Mathew41.78927490000000-87.601250000000001936Mathew, BijiRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorStephenArcherStephen Archer41.78927490000000-87.601250000000002615Archer, StephenProfessor37913908Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deuitch NT, Farhadfar N, Gergis U, Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, Godley LA, Lai CTransplantation and cellular therapyDonor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2024 Mar; 30(3):255-267.Transplant Cell Ther2023-10-31T00:00:002023Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.true1true1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor27480287Won B, Mambetsariev I, Salgia RBMC cancerPost-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568.BMC Cancer2016-08-02T00:00:002016Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.